ArticleBritish journal of pharmacology2007
Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.
Article in British journal of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 64 citations in OpenAlex.
- Ultra low-dose naloxone and tramadol/acetaminophen in elderly patients undergoing joint replacement surgery: a pilot study.Pain research & managementTrial
- Differential Effects of a Novel Opioid Ligand UTA1003 on Antinociceptive Tolerance and Motor Behaviour.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Endogenous opioid systems alterations in pain and opioid use disorder.Frontiers in systems neuroscience · 2022Review
- Opioid Analgesia and Opioid-Induced Adverse Effects: A Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Opioid-Induced Signaling and Antinociception Are Modulated by the Recently Deorphanized Receptor, GPR171.The Journal of pharmacology and experimental therapeutics · 2019Article
- Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.The European journal of neuroscience · 2015Article
- Ligand requirements for involvement of PKCε in synergistic analgesic interactions between spinal μ and δ opioid receptors.British journal of pharmacology · 2015Article
- Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.British journal of pharmacology · 2015Review
- Prolonged morphine treatment alters δ opioid receptor post-internalization trafficking.British journal of pharmacology · 2015Article
- Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochemical pharmacology · 2014Article
- Combined administration of oxycodone/naloxone in chronic osteo-articular diseases pain therapy.Translational medicine @ UniSa · 2014Review
- An integrated quantitative proteomics and systems biology approach to explore synaptic protein profile changes during morphine exposure.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Review
- Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.Progress in molecular biology and translational science · 2013Review
- Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism.PloS one · 2013Article
- Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology.Drug and alcohol dependence · 2012Review
- Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain.PloS one · 2012Article
- Effects of combined opioids on pain and mood in mammals.Pain research and treatment · 2012Article
- G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding.Molecular pharmacology · 2011Article
- Exploring a role for heteromerization in GPCR signalling specificity.The Biochemical journal · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeUltralow doses of naltrexone, a non-selective opioid antagonist, have previously been found to augment acute morphine analgesia and block the development of tolerance to this effect. Since morphine tolerance is dependent on the activity of micro and delta receptors, the present study investigated the effects of ultralow doses of antagonists selective for these receptor types on morphine analgesia and tolerance in tests of thermal and mechanical nociception. EXPERIMENTAL APPROACH: Effects of intrathecal administration of mu-receptor antagonists, CTOP (0.01 ng) or CTAP (0.001 ng), or a delta-receptor antagonist, naltrindole (0.01 ng), on spinal morphine analgesia and tolerance were evaluated using the tail-flick and paw-pressure tests in rats. KEY
resultsBoth micro and delta antagonists augmented analgesia produced by a sub-maximal (5 microg) or maximal (15 microg) dose of morphine. Administration of the antagonists with morphine (15 microg) for 5 days inhibited the progressive decline of analgesia and prevented the loss of morphine potency. In animals exhibiting tolerance to morphine, administration of the antagonists with morphine produced a recovery of the analgesic response and restored morphine potency. CONCLUSIONS AND IMPLICATIONS: Combining ultralow doses of micro- or delta-receptor antagonists with spinal morphine augmented the acute analgesic effects, inhibited the induction of chronic tolerance and reversed established tolerance. The remarkably similar effects of micro- and delta-opioid receptor antagonists on morphine analgesia and tolerance are interpreted in terms of blockade of the latent excitatory effects of the agonist that limit expression of its full activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.